The trademark application CORVAL was filed by Corval LLC, a Limited Liability Company (the "Applicant"). The application was published for oppositions on February 9, 2022, and it was registered by office on May 19, 2022 without any oppositions.
The application was filed in English (German was selected as the second language).
Change of name and professional address of the trademark registration was recorded on June 18, 2023.
Goods And Services
The mark was filed in class 35 with Consulting services in the fields of life sciences and biotechnology, namely, providing business planning and strategy services to manufacturers relating to the commercialization of new pharmaceutical drugs, biopharmaceuticals, and therapeutics for the treatment of disease and Consulting services in the fields of life sciences and biotechnology, namely, providing strategic roadmaps to manufacturers to inform business planning, identify objectives and track activities relating to the commercialization of new pharmaceutical drugs, biopharmaceuticals, and therapeutics for the treatment of disease..
The mark was filed in class 42 with following description of goods:
Providing software as a service (SaaS), namely, non-downloadable web-based software for use by manufacturers in the fields of life sciences and pharmaceuticals for facilitating and streamlining the commercialization of new pharmaceutical drugs, biopharmaceuticals, and therapeutics for the treatment of disease
Providing collaborative planning and technology solutions to manufacturers in the fields of life sciences and pharmaceuticals, namely, providing web-based software for cloud-based collaboration and strategic planning relating to the commercialization of new pharmaceutical drugs, biopharmaceuticals, and therapeutics for the treatment of disease
Development and implementation of collaborative planning and technology solutions for use by manufacturers in the fields of life sciences and pharmaceuticals, namely, development and implementation of web-based software that enables users to connect and collaborate with each other to plan business and market entry strategies relating to the commercialization of new pharmaceutical drugs, biopharmaceuticals, and therapeutics for the treatment of disease.